nodes	percent_of_prediction	percent_of_DWPC	metapath
Benzatropine—CYP2C19—prostate cancer	0.357	1	CbGaD
Benzatropine—CYP2C19—Bicalutamide—prostate cancer	0.0803	0.201	CbGbCtD
Benzatropine—CYP2C19—Nilutamide—prostate cancer	0.0803	0.201	CbGbCtD
Benzatropine—CYP2C19—Flutamide—prostate cancer	0.0666	0.167	CbGbCtD
Benzatropine—CYP2D6—Bicalutamide—prostate cancer	0.0611	0.153	CbGbCtD
Benzatropine—CYP2D6—Abiraterone—prostate cancer	0.0506	0.127	CbGbCtD
Benzatropine—CYP2C19—Estradiol—prostate cancer	0.0276	0.0692	CbGbCtD
Benzatropine—CYP2C19—Prednisone—prostate cancer	0.0238	0.0595	CbGbCtD
Benzatropine—CYP2D6—Doxorubicin—prostate cancer	0.00936	0.0234	CbGbCtD
Benzatropine—Cyclizine—SULT1E1—prostate cancer	0.00192	0.438	CrCbGaD
Benzatropine—Nervousness—Flutamide—prostate cancer	0.00107	0.00808	CcSEcCtD
Benzatropine—Hypoaesthesia—Cabazitaxel—prostate cancer	0.00107	0.00804	CcSEcCtD
Benzatropine—Disorientation—Conjugated Estrogens—prostate cancer	0.00102	0.00772	CcSEcCtD
Benzatropine—Tension—Estradiol valerate/Dienogest—prostate cancer	0.00102	0.00771	CcSEcCtD
Benzatropine—Nervousness—Estradiol valerate/Dienogest—prostate cancer	0.00101	0.00763	CcSEcCtD
Benzatropine—Cerebrovascular accident—Goserelin—prostate cancer	0.000944	0.00711	CcSEcCtD
Benzatropine—Cerebrovascular accident—Conjugated Estrogens—prostate cancer	0.000936	0.00704	CcSEcCtD
Benzatropine—Vision blurred—Degarelix—prostate cancer	0.000934	0.00704	CcSEcCtD
Benzatropine—Dry mouth—Nilutamide—prostate cancer	0.000924	0.00696	CcSEcCtD
Benzatropine—Ileus—Docetaxel—prostate cancer	0.00092	0.00693	CcSEcCtD
Benzatropine—Confusional state—Flutamide—prostate cancer	0.000909	0.00685	CcSEcCtD
Benzatropine—Dysuria—Ethinyl Estradiol—prostate cancer	0.000909	0.00684	CcSEcCtD
Benzatropine—Psychotic disorder—Goserelin—prostate cancer	0.000904	0.00681	CcSEcCtD
Benzatropine—Ileus—Capecitabine—prostate cancer	0.000891	0.00671	CcSEcCtD
Benzatropine—Decreased appetite—Estramustine—prostate cancer	0.000887	0.00668	CcSEcCtD
Benzatropine—Urinary retention—Goserelin—prostate cancer	0.00088	0.00663	CcSEcCtD
Benzatropine—Constipation—Abiraterone—prostate cancer	0.000848	0.00638	CcSEcCtD
Benzatropine—Dry mouth—Degarelix—prostate cancer	0.000826	0.00622	CcSEcCtD
Benzatropine—Memory impairment—Capecitabine—prostate cancer	0.000803	0.00605	CcSEcCtD
Benzatropine—Dysphagia—Conjugated Estrogens—prostate cancer	0.000792	0.00597	CcSEcCtD
Benzatropine—Decreased appetite—Nilutamide—prostate cancer	0.000787	0.00593	CcSEcCtD
Benzatropine—Tension—Bicalutamide—prostate cancer	0.000786	0.00592	CcSEcCtD
Benzatropine—Decreased appetite—Flutamide—prostate cancer	0.000784	0.0059	CcSEcCtD
Benzatropine—Body temperature increased—Abiraterone—prostate cancer	0.000784	0.0059	CcSEcCtD
Benzatropine—Nervousness—Bicalutamide—prostate cancer	0.000778	0.00586	CcSEcCtD
Benzatropine—Dry mouth—Cabazitaxel—prostate cancer	0.000778	0.00586	CcSEcCtD
Benzatropine—Constipation—Nilutamide—prostate cancer	0.000775	0.00583	CcSEcCtD
Benzatropine—Hypoaesthesia—Ethinyl Estradiol—prostate cancer	0.000774	0.00583	CcSEcCtD
Benzatropine—Constipation—Flutamide—prostate cancer	0.000771	0.00581	CcSEcCtD
Benzatropine—Confusional state—Cabazitaxel—prostate cancer	0.000769	0.00579	CcSEcCtD
Benzatropine—Cerebrovascular accident—Estradiol—prostate cancer	0.000749	0.00564	CcSEcCtD
Benzatropine—Dysuria—Goserelin—prostate cancer	0.000748	0.00563	CcSEcCtD
Benzatropine—Feeling abnormal—Nilutamide—prostate cancer	0.000746	0.00562	CcSEcCtD
Benzatropine—Tachycardia—Cabazitaxel—prostate cancer	0.000744	0.0056	CcSEcCtD
Benzatropine—Feeling abnormal—Flutamide—prostate cancer	0.000743	0.0056	CcSEcCtD
Benzatropine—Dysuria—Conjugated Estrogens—prostate cancer	0.000741	0.00558	CcSEcCtD
Benzatropine—Body temperature increased—Nilutamide—prostate cancer	0.000716	0.00539	CcSEcCtD
Benzatropine—Memory impairment—Prednisone—prostate cancer	0.000715	0.00539	CcSEcCtD
Benzatropine—Decreased appetite—Degarelix—prostate cancer	0.000703	0.0053	CcSEcCtD
Benzatropine—Constipation—Degarelix—prostate cancer	0.000692	0.00521	CcSEcCtD
Benzatropine—Dry mouth—Bicalutamide—prostate cancer	0.000667	0.00502	CcSEcCtD
Benzatropine—Feeling abnormal—Degarelix—prostate cancer	0.000667	0.00502	CcSEcCtD
Benzatropine—Decreased appetite—Cabazitaxel—prostate cancer	0.000663	0.00499	CcSEcCtD
Benzatropine—Confusional state—Bicalutamide—prostate cancer	0.000659	0.00496	CcSEcCtD
Benzatropine—Constipation—Cabazitaxel—prostate cancer	0.000652	0.00491	CcSEcCtD
Benzatropine—Vomiting—Estramustine—prostate cancer	0.000649	0.00489	CcSEcCtD
Benzatropine—Rash—Estramustine—prostate cancer	0.000644	0.00485	CcSEcCtD
Benzatropine—Dermatitis—Estramustine—prostate cancer	0.000643	0.00484	CcSEcCtD
Benzatropine—Body temperature increased—Degarelix—prostate cancer	0.00064	0.00482	CcSEcCtD
Benzatropine—Dysphagia—Estradiol—prostate cancer	0.000634	0.00477	CcSEcCtD
Benzatropine—Hypoaesthesia—Conjugated Estrogens—prostate cancer	0.000631	0.00475	CcSEcCtD
Benzatropine—Vomiting—Abiraterone—prostate cancer	0.00063	0.00475	CcSEcCtD
Benzatropine—Feeling abnormal—Cabazitaxel—prostate cancer	0.000628	0.00473	CcSEcCtD
Benzatropine—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000627	0.00472	CcSEcCtD
Benzatropine—Rash—Abiraterone—prostate cancer	0.000625	0.00471	CcSEcCtD
Benzatropine—Dermatitis—Abiraterone—prostate cancer	0.000625	0.0047	CcSEcCtD
Benzatropine—Ileus—Epirubicin—prostate cancer	0.00062	0.00467	CcSEcCtD
Benzatropine—Vomiting—Estrone—prostate cancer	0.00062	0.00467	CcSEcCtD
Benzatropine—Rash—Estrone—prostate cancer	0.000615	0.00463	CcSEcCtD
Benzatropine—Dermatitis—Estrone—prostate cancer	0.000614	0.00463	CcSEcCtD
Benzatropine—Nausea—Estramustine—prostate cancer	0.000606	0.00457	CcSEcCtD
Benzatropine—Body temperature increased—Cabazitaxel—prostate cancer	0.000603	0.00454	CcSEcCtD
Benzatropine—Hypersensitivity—Degarelix—prostate cancer	0.000596	0.00449	CcSEcCtD
Benzatropine—Nausea—Estrone—prostate cancer	0.000579	0.00436	CcSEcCtD
Benzatropine—Vomiting—Nilutamide—prostate cancer	0.000576	0.00434	CcSEcCtD
Benzatropine—Ileus—Doxorubicin—prostate cancer	0.000574	0.00432	CcSEcCtD
Benzatropine—Vomiting—Flutamide—prostate cancer	0.000573	0.00432	CcSEcCtD
Benzatropine—Rash—Nilutamide—prostate cancer	0.000571	0.0043	CcSEcCtD
Benzatropine—Dermatitis—Nilutamide—prostate cancer	0.000571	0.0043	CcSEcCtD
Benzatropine—Rash—Flutamide—prostate cancer	0.000569	0.00428	CcSEcCtD
Benzatropine—Decreased appetite—Bicalutamide—prostate cancer	0.000568	0.00428	CcSEcCtD
Benzatropine—Dermatitis—Flutamide—prostate cancer	0.000568	0.00428	CcSEcCtD
Benzatropine—Hypersensitivity—Cabazitaxel—prostate cancer	0.000562	0.00423	CcSEcCtD
Benzatropine—Constipation—Bicalutamide—prostate cancer	0.000559	0.00421	CcSEcCtD
Benzatropine—Tension—Goserelin—prostate cancer	0.000547	0.00412	CcSEcCtD
Benzatropine—Tension—Conjugated Estrogens—prostate cancer	0.000542	0.00408	CcSEcCtD
Benzatropine—Nervousness—Goserelin—prostate cancer	0.000541	0.00408	CcSEcCtD
Benzatropine—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.000541	0.00407	CcSEcCtD
Benzatropine—Feeling abnormal—Bicalutamide—prostate cancer	0.000539	0.00406	CcSEcCtD
Benzatropine—Nausea—Nilutamide—prostate cancer	0.000538	0.00405	CcSEcCtD
Benzatropine—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000537	0.00404	CcSEcCtD
Benzatropine—Nervousness—Conjugated Estrogens—prostate cancer	0.000536	0.00404	CcSEcCtD
Benzatropine—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000536	0.00404	CcSEcCtD
Benzatropine—Nausea—Flutamide—prostate cancer	0.000536	0.00403	CcSEcCtD
Benzatropine—Vision blurred—Goserelin—prostate cancer	0.000525	0.00396	CcSEcCtD
Benzatropine—Vision blurred—Conjugated Estrogens—prostate cancer	0.00052	0.00392	CcSEcCtD
Benzatropine—Body temperature increased—Bicalutamide—prostate cancer	0.000517	0.00389	CcSEcCtD
Benzatropine—Vomiting—Degarelix—prostate cancer	0.000514	0.00387	CcSEcCtD
Benzatropine—Rash—Degarelix—prostate cancer	0.00051	0.00384	CcSEcCtD
Benzatropine—Dermatitis—Degarelix—prostate cancer	0.00051	0.00384	CcSEcCtD
Benzatropine—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000506	0.00381	CcSEcCtD
Benzatropine—Hypoaesthesia—Estradiol—prostate cancer	0.000505	0.0038	CcSEcCtD
Benzatropine—Dysphagia—Etoposide—prostate cancer	0.000491	0.0037	CcSEcCtD
Benzatropine—Vomiting—Cabazitaxel—prostate cancer	0.000485	0.00365	CcSEcCtD
Benzatropine—Hypersensitivity—Bicalutamide—prostate cancer	0.000482	0.00363	CcSEcCtD
Benzatropine—Nausea—Degarelix—prostate cancer	0.000481	0.00362	CcSEcCtD
Benzatropine—Constipation—Ethinyl Estradiol—prostate cancer	0.000473	0.00356	CcSEcCtD
Benzatropine—Cerebrovascular accident—Capecitabine—prostate cancer	0.000467	0.00352	CcSEcCtD
Benzatropine—Dry mouth—Goserelin—prostate cancer	0.000464	0.00349	CcSEcCtD
Benzatropine—Confusional state—Goserelin—prostate cancer	0.000459	0.00345	CcSEcCtD
Benzatropine—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.000455	0.00343	CcSEcCtD
Benzatropine—Nausea—Cabazitaxel—prostate cancer	0.000453	0.00341	CcSEcCtD
Benzatropine—Tachycardia—Goserelin—prostate cancer	0.000444	0.00334	CcSEcCtD
Benzatropine—Tachycardia—Conjugated Estrogens—prostate cancer	0.00044	0.00331	CcSEcCtD
Benzatropine—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.000437	0.00329	CcSEcCtD
Benzatropine—Urinary retention—Capecitabine—prostate cancer	0.000435	0.00328	CcSEcCtD
Benzatropine—Tension—Estradiol—prostate cancer	0.000434	0.00326	CcSEcCtD
Benzatropine—Nervousness—Estradiol—prostate cancer	0.000429	0.00323	CcSEcCtD
Benzatropine—Vomiting—Bicalutamide—prostate cancer	0.000416	0.00313	CcSEcCtD
Benzatropine—Rash—Bicalutamide—prostate cancer	0.000412	0.0031	CcSEcCtD
Benzatropine—Dermatitis—Bicalutamide—prostate cancer	0.000412	0.0031	CcSEcCtD
Benzatropine—Dysphagia—Docetaxel—prostate cancer	0.000408	0.00308	CcSEcCtD
Benzatropine—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000407	0.00307	CcSEcCtD
Benzatropine—Psychotic disorder—Prednisone—prostate cancer	0.000398	0.003	CcSEcCtD
Benzatropine—Dysphagia—Capecitabine—prostate cancer	0.000395	0.00298	CcSEcCtD
Benzatropine—Decreased appetite—Goserelin—prostate cancer	0.000395	0.00298	CcSEcCtD
Benzatropine—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000392	0.00295	CcSEcCtD
Benzatropine—Hypoaesthesia—Etoposide—prostate cancer	0.000391	0.00295	CcSEcCtD
Benzatropine—Constipation—Goserelin—prostate cancer	0.000389	0.00293	CcSEcCtD
Benzatropine—Nausea—Bicalutamide—prostate cancer	0.000388	0.00292	CcSEcCtD
Benzatropine—Vision blurred—Mitoxantrone—prostate cancer	0.000388	0.00292	CcSEcCtD
Benzatropine—Constipation—Conjugated Estrogens—prostate cancer	0.000385	0.0029	CcSEcCtD
Benzatropine—Feeling abnormal—Goserelin—prostate cancer	0.000375	0.00282	CcSEcCtD
Benzatropine—Dysuria—Capecitabine—prostate cancer	0.00037	0.00278	CcSEcCtD
Benzatropine—Dry mouth—Estradiol—prostate cancer	0.000368	0.00277	CcSEcCtD
Benzatropine—Confusional state—Estradiol—prostate cancer	0.000364	0.00274	CcSEcCtD
Benzatropine—Body temperature increased—Goserelin—prostate cancer	0.00036	0.00271	CcSEcCtD
Benzatropine—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000356	0.00268	CcSEcCtD
Benzatropine—Tachycardia—Estradiol—prostate cancer	0.000352	0.00265	CcSEcCtD
Benzatropine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000351	0.00265	CcSEcCtD
Benzatropine—Rash—Ethinyl Estradiol—prostate cancer	0.000349	0.00262	CcSEcCtD
Benzatropine—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000348	0.00262	CcSEcCtD
Benzatropine—Confusional state—Mitoxantrone—prostate cancer	0.000339	0.00255	CcSEcCtD
Benzatropine—Hypersensitivity—Goserelin—prostate cancer	0.000335	0.00252	CcSEcCtD
Benzatropine—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000332	0.0025	CcSEcCtD
Benzatropine—Nausea—Ethinyl Estradiol—prostate cancer	0.000328	0.00247	CcSEcCtD
Benzatropine—Tachycardia—Mitoxantrone—prostate cancer	0.000328	0.00247	CcSEcCtD
Benzatropine—Hypoaesthesia—Docetaxel—prostate cancer	0.000325	0.00245	CcSEcCtD
Benzatropine—Cerebrovascular accident—Epirubicin—prostate cancer	0.000325	0.00245	CcSEcCtD
Benzatropine—Hypoaesthesia—Capecitabine—prostate cancer	0.000315	0.00237	CcSEcCtD
Benzatropine—Decreased appetite—Estradiol—prostate cancer	0.000313	0.00236	CcSEcCtD
Benzatropine—Constipation—Estradiol—prostate cancer	0.000308	0.00232	CcSEcCtD
Benzatropine—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000301	0.00227	CcSEcCtD
Benzatropine—Feeling abnormal—Estradiol—prostate cancer	0.000297	0.00224	CcSEcCtD
Benzatropine—Decreased appetite—Mitoxantrone—prostate cancer	0.000292	0.0022	CcSEcCtD
Benzatropine—Vomiting—Goserelin—prostate cancer	0.000289	0.00218	CcSEcCtD
Benzatropine—Constipation—Mitoxantrone—prostate cancer	0.000287	0.00216	CcSEcCtD
Benzatropine—Rash—Goserelin—prostate cancer	0.000287	0.00216	CcSEcCtD
Benzatropine—Dermatitis—Goserelin—prostate cancer	0.000287	0.00216	CcSEcCtD
Benzatropine—Vomiting—Conjugated Estrogens—prostate cancer	0.000286	0.00216	CcSEcCtD
Benzatropine—Body temperature increased—Estradiol—prostate cancer	0.000285	0.00215	CcSEcCtD
Benzatropine—Rash—Conjugated Estrogens—prostate cancer	0.000284	0.00214	CcSEcCtD
Benzatropine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000284	0.00214	CcSEcCtD
Benzatropine—Confusional state—Etoposide—prostate cancer	0.000282	0.00212	CcSEcCtD
Benzatropine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000277	0.00208	CcSEcCtD
Benzatropine—Dysphagia—Epirubicin—prostate cancer	0.000275	0.00207	CcSEcCtD
Benzatropine—Tachycardia—Etoposide—prostate cancer	0.000273	0.00205	CcSEcCtD
Benzatropine—Nausea—Goserelin—prostate cancer	0.00027	0.00203	CcSEcCtD
Benzatropine—Nausea—Conjugated Estrogens—prostate cancer	0.000268	0.00202	CcSEcCtD
Benzatropine—Hypersensitivity—Estradiol—prostate cancer	0.000266	0.002	CcSEcCtD
Benzatropine—Body temperature increased—Mitoxantrone—prostate cancer	0.000266	0.002	CcSEcCtD
Benzatropine—Vision blurred—Capecitabine—prostate cancer	0.00026	0.00196	CcSEcCtD
Benzatropine—Dysuria—Epirubicin—prostate cancer	0.000258	0.00194	CcSEcCtD
Benzatropine—Dysphagia—Doxorubicin—prostate cancer	0.000255	0.00192	CcSEcCtD
Benzatropine—Diphenhydramine—CYP2C18—prostate cancer	0.000248	0.0565	CrCbGaD
Benzatropine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000248	0.00186	CcSEcCtD
Benzatropine—Decreased appetite—Etoposide—prostate cancer	0.000243	0.00183	CcSEcCtD
Benzatropine—Constipation—Etoposide—prostate cancer	0.000239	0.0018	CcSEcCtD
Benzatropine—Dysuria—Doxorubicin—prostate cancer	0.000238	0.00179	CcSEcCtD
Benzatropine—Dry mouth—Docetaxel—prostate cancer	0.000237	0.00178	CcSEcCtD
Benzatropine—Modafinil—CYP3A5—prostate cancer	0.000235	0.0536	CrCbGaD
Benzatropine—Confusional state—Docetaxel—prostate cancer	0.000234	0.00176	CcSEcCtD
Benzatropine—Vision blurred—Prednisone—prostate cancer	0.000231	0.00174	CcSEcCtD
Benzatropine—Feeling abnormal—Etoposide—prostate cancer	0.00023	0.00173	CcSEcCtD
Benzatropine—Fentanyl—CYP3A5—prostate cancer	0.00023	0.0524	CrCbGaD
Benzatropine—Dry mouth—Capecitabine—prostate cancer	0.000229	0.00173	CcSEcCtD
Benzatropine—Vomiting—Estradiol—prostate cancer	0.000229	0.00173	CcSEcCtD
Benzatropine—Rash—Estradiol—prostate cancer	0.000227	0.00171	CcSEcCtD
Benzatropine—Dermatitis—Estradiol—prostate cancer	0.000227	0.00171	CcSEcCtD
Benzatropine—Confusional state—Capecitabine—prostate cancer	0.000227	0.00171	CcSEcCtD
Benzatropine—Tachycardia—Docetaxel—prostate cancer	0.000227	0.00171	CcSEcCtD
Benzatropine—Body temperature increased—Etoposide—prostate cancer	0.000221	0.00166	CcSEcCtD
Benzatropine—Cinnarizine—CYP2A6—prostate cancer	0.00022	0.0502	CrCbGaD
Benzatropine—Tachycardia—Capecitabine—prostate cancer	0.000219	0.00165	CcSEcCtD
Benzatropine—Hypoaesthesia—Epirubicin—prostate cancer	0.000219	0.00165	CcSEcCtD
Benzatropine—Reboxetine—CYP3A4—prostate cancer	0.000217	0.0496	CrCbGaD
Benzatropine—Nausea—Estradiol—prostate cancer	0.000214	0.00161	CcSEcCtD
Benzatropine—Vomiting—Mitoxantrone—prostate cancer	0.000214	0.00161	CcSEcCtD
Benzatropine—Rash—Mitoxantrone—prostate cancer	0.000212	0.0016	CcSEcCtD
Benzatropine—Dermatitis—Mitoxantrone—prostate cancer	0.000212	0.00159	CcSEcCtD
Benzatropine—Hypersensitivity—Etoposide—prostate cancer	0.000206	0.00155	CcSEcCtD
Benzatropine—Hypoaesthesia—Doxorubicin—prostate cancer	0.000203	0.00153	CcSEcCtD
Benzatropine—Diphenhydramine—SLC22A1—prostate cancer	0.000202	0.0462	CrCbGaD
Benzatropine—Decreased appetite—Docetaxel—prostate cancer	0.000202	0.00152	CcSEcCtD
Benzatropine—Nausea—Mitoxantrone—prostate cancer	0.0002	0.0015	CcSEcCtD
Benzatropine—Constipation—Docetaxel—prostate cancer	0.000199	0.0015	CcSEcCtD
Benzatropine—Tachycardia—Prednisone—prostate cancer	0.000196	0.00147	CcSEcCtD
Benzatropine—Decreased appetite—Capecitabine—prostate cancer	0.000195	0.00147	CcSEcCtD
Benzatropine—Constipation—Capecitabine—prostate cancer	0.000192	0.00145	CcSEcCtD
Benzatropine—Feeling abnormal—Docetaxel—prostate cancer	0.000191	0.00144	CcSEcCtD
Benzatropine—Tension—Epirubicin—prostate cancer	0.000188	0.00142	CcSEcCtD
Benzatropine—Nervousness—Epirubicin—prostate cancer	0.000186	0.0014	CcSEcCtD
Benzatropine—Feeling abnormal—Capecitabine—prostate cancer	0.000185	0.0014	CcSEcCtD
Benzatropine—Body temperature increased—Docetaxel—prostate cancer	0.000184	0.00138	CcSEcCtD
Benzatropine—Vision blurred—Epirubicin—prostate cancer	0.000181	0.00136	CcSEcCtD
Benzatropine—Body temperature increased—Capecitabine—prostate cancer	0.000178	0.00134	CcSEcCtD
Benzatropine—Vomiting—Etoposide—prostate cancer	0.000178	0.00134	CcSEcCtD
Benzatropine—Rash—Etoposide—prostate cancer	0.000176	0.00133	CcSEcCtD
Benzatropine—Dermatitis—Etoposide—prostate cancer	0.000176	0.00133	CcSEcCtD
Benzatropine—Tension—Doxorubicin—prostate cancer	0.000174	0.00131	CcSEcCtD
Benzatropine—Decreased appetite—Prednisone—prostate cancer	0.000174	0.00131	CcSEcCtD
Benzatropine—Nervousness—Doxorubicin—prostate cancer	0.000173	0.0013	CcSEcCtD
Benzatropine—Constipation—Prednisone—prostate cancer	0.000171	0.00129	CcSEcCtD
Benzatropine—Hypersensitivity—Docetaxel—prostate cancer	0.000171	0.00129	CcSEcCtD
Benzatropine—Vision blurred—Doxorubicin—prostate cancer	0.000167	0.00126	CcSEcCtD
Benzatropine—Nausea—Etoposide—prostate cancer	0.000166	0.00125	CcSEcCtD
Benzatropine—Hypersensitivity—Capecitabine—prostate cancer	0.000166	0.00125	CcSEcCtD
Benzatropine—Feeling abnormal—Prednisone—prostate cancer	0.000165	0.00124	CcSEcCtD
Benzatropine—Modafinil—CYP2C19—prostate cancer	0.00016	0.0365	CrCbGaD
Benzatropine—Dry mouth—Epirubicin—prostate cancer	0.00016	0.0012	CcSEcCtD
Benzatropine—Body temperature increased—Prednisone—prostate cancer	0.000158	0.00119	CcSEcCtD
Benzatropine—Confusional state—Epirubicin—prostate cancer	0.000158	0.00119	CcSEcCtD
Benzatropine—Cinnarizine—CYP1A1—prostate cancer	0.000154	0.0352	CrCbGaD
Benzatropine—Tachycardia—Epirubicin—prostate cancer	0.000153	0.00115	CcSEcCtD
Benzatropine—Dry mouth—Doxorubicin—prostate cancer	0.000148	0.00111	CcSEcCtD
Benzatropine—Vomiting—Docetaxel—prostate cancer	0.000148	0.00111	CcSEcCtD
Benzatropine—Hypersensitivity—Prednisone—prostate cancer	0.000148	0.00111	CcSEcCtD
Benzatropine—Rash—Docetaxel—prostate cancer	0.000146	0.0011	CcSEcCtD
Benzatropine—Dermatitis—Docetaxel—prostate cancer	0.000146	0.0011	CcSEcCtD
Benzatropine—Confusional state—Doxorubicin—prostate cancer	0.000146	0.0011	CcSEcCtD
Benzatropine—Vomiting—Capecitabine—prostate cancer	0.000143	0.00108	CcSEcCtD
Benzatropine—Rash—Capecitabine—prostate cancer	0.000142	0.00107	CcSEcCtD
Benzatropine—Dermatitis—Capecitabine—prostate cancer	0.000142	0.00107	CcSEcCtD
Benzatropine—Tachycardia—Doxorubicin—prostate cancer	0.000141	0.00107	CcSEcCtD
Benzatropine—Nausea—Docetaxel—prostate cancer	0.000138	0.00104	CcSEcCtD
Benzatropine—Atomoxetine—CYP2C19—prostate cancer	0.000138	0.0314	CrCbGaD
Benzatropine—Decreased appetite—Epirubicin—prostate cancer	0.000136	0.00103	CcSEcCtD
Benzatropine—Constipation—Epirubicin—prostate cancer	0.000134	0.00101	CcSEcCtD
Benzatropine—Nausea—Capecitabine—prostate cancer	0.000134	0.00101	CcSEcCtD
Benzatropine—Feeling abnormal—Epirubicin—prostate cancer	0.000129	0.000972	CcSEcCtD
Benzatropine—Vomiting—Prednisone—prostate cancer	0.000127	0.000959	CcSEcCtD
Benzatropine—Rash—Prednisone—prostate cancer	0.000126	0.000951	CcSEcCtD
Benzatropine—Dermatitis—Prednisone—prostate cancer	0.000126	0.00095	CcSEcCtD
Benzatropine—Decreased appetite—Doxorubicin—prostate cancer	0.000126	0.000949	CcSEcCtD
Benzatropine—Constipation—Doxorubicin—prostate cancer	0.000124	0.000933	CcSEcCtD
Benzatropine—Body temperature increased—Epirubicin—prostate cancer	0.000124	0.000932	CcSEcCtD
Benzatropine—Feeling abnormal—Doxorubicin—prostate cancer	0.000119	0.000899	CcSEcCtD
Benzatropine—Nausea—Prednisone—prostate cancer	0.000119	0.000896	CcSEcCtD
Benzatropine—Hypersensitivity—Epirubicin—prostate cancer	0.000115	0.000869	CcSEcCtD
Benzatropine—Body temperature increased—Doxorubicin—prostate cancer	0.000115	0.000863	CcSEcCtD
Benzatropine—Diphenhydramine—CYP2C19—prostate cancer	0.000111	0.0254	CrCbGaD
Benzatropine—Hypersensitivity—Doxorubicin—prostate cancer	0.000107	0.000804	CcSEcCtD
Benzatropine—Orphenadrine—CYP2E1—prostate cancer	0.000106	0.0242	CrCbGaD
Benzatropine—Modafinil—CYP3A4—prostate cancer	0.000102	0.0232	CrCbGaD
Benzatropine—Vomiting—Epirubicin—prostate cancer	9.96e-05	0.00075	CcSEcCtD
Benzatropine—Fentanyl—CYP3A4—prostate cancer	9.96e-05	0.0227	CrCbGaD
Benzatropine—Rash—Epirubicin—prostate cancer	9.88e-05	0.000744	CcSEcCtD
Benzatropine—Dermatitis—Epirubicin—prostate cancer	9.87e-05	0.000743	CcSEcCtD
Benzatropine—Nausea—Epirubicin—prostate cancer	9.31e-05	0.000701	CcSEcCtD
Benzatropine—Vomiting—Doxorubicin—prostate cancer	9.22e-05	0.000694	CcSEcCtD
Benzatropine—Rash—Doxorubicin—prostate cancer	9.14e-05	0.000688	CcSEcCtD
Benzatropine—Dermatitis—Doxorubicin—prostate cancer	9.13e-05	0.000688	CcSEcCtD
Benzatropine—Benzphetamine—CYP3A4—prostate cancer	8.83e-05	0.0201	CrCbGaD
Benzatropine—Atomoxetine—CYP3A4—prostate cancer	8.76e-05	0.02	CrCbGaD
Benzatropine—Nausea—Doxorubicin—prostate cancer	8.61e-05	0.000648	CcSEcCtD
Benzatropine—Orphenadrine—CYP3A4—prostate cancer	6.69e-05	0.0152	CrCbGaD
Benzatropine—CHRM2—Signaling by GPCR—JAK2—prostate cancer	8.5e-06	8.04e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—TH—prostate cancer	8.46e-06	8e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	8.4e-06	7.95e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—CYP3A4—prostate cancer	8.37e-06	7.91e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—LPL—prostate cancer	8.36e-06	7.9e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—LPL—prostate cancer	8.33e-06	7.88e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	8.33e-06	7.87e-05	CbGpPWpGaD
Benzatropine—HRH1—GPCR downstream signaling—IL2—prostate cancer	8.29e-06	7.84e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—PDGFRB—prostate cancer	8.28e-06	7.83e-05	CbGpPWpGaD
Benzatropine—CHRM1—GPCR downstream signaling—IL2—prostate cancer	8.27e-06	7.82e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—PDGFRB—prostate cancer	8.26e-06	7.81e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—CYP1B1—prostate cancer	8.23e-06	7.78e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—LPL—prostate cancer	8.22e-06	7.78e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—PIK3CB—prostate cancer	8.2e-06	7.76e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—PIK3CB—prostate cancer	8.18e-06	7.73e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—SLC5A5—prostate cancer	8.17e-06	7.73e-05	CbGpPWpGaD
Benzatropine—CHRM2—GPCR downstream signaling—IL2—prostate cancer	8.16e-06	7.72e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	8.15e-06	7.71e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—ITGB3—prostate cancer	8.07e-06	7.63e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	8.07e-06	7.63e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—ITGB3—prostate cancer	8.05e-06	7.61e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—CYP2E1—prostate cancer	7.98e-06	7.55e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—GGT1—prostate cancer	7.97e-06	7.54e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—ITGB3—prostate cancer	7.94e-06	7.51e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—NQO1—prostate cancer	7.89e-06	7.47e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—CXCL8—prostate cancer	7.88e-06	7.45e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	7.86e-06	7.43e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—NCOA1—prostate cancer	7.85e-06	7.42e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—ERBB3—prostate cancer	7.83e-06	7.4e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—FGFR2—prostate cancer	7.82e-06	7.39e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—ERBB3—prostate cancer	7.81e-06	7.38e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—FGFR2—prostate cancer	7.79e-06	7.37e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—TH—prostate cancer	7.78e-06	7.36e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	7.76e-06	7.33e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—CYP19A1—prostate cancer	7.74e-06	7.32e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—ERBB3—prostate cancer	7.7e-06	7.29e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—CYP3A4—prostate cancer	7.7e-06	7.28e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—FGFR2—prostate cancer	7.69e-06	7.27e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—CYP1B1—prostate cancer	7.57e-06	7.16e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—IL2—prostate cancer	7.53e-06	7.12e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—IL2—prostate cancer	7.51e-06	7.1e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—TERT—prostate cancer	7.5e-06	7.1e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—TERT—prostate cancer	7.48e-06	7.07e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—RXRA—prostate cancer	7.47e-06	7.06e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—IL2—prostate cancer	7.41e-06	7.01e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—TERT—prostate cancer	7.38e-06	6.98e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—GGT1—prostate cancer	7.33e-06	6.93e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.26e-06	6.87e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—NCOA1—prostate cancer	7.22e-06	6.83e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—COMT—prostate cancer	7.19e-06	6.8e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—HIF1A—prostate cancer	7.18e-06	6.79e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—GSTP1—prostate cancer	7.16e-06	6.77e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—HIF1A—prostate cancer	7.15e-06	6.77e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—CYP19A1—prostate cancer	7.12e-06	6.73e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—HIF1A—prostate cancer	7.06e-06	6.68e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—ITPR1—prostate cancer	7.04e-06	6.66e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—LEP—prostate cancer	7.01e-06	6.63e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—LEP—prostate cancer	6.98e-06	6.6e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CAV1—prostate cancer	6.94e-06	6.56e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.93e-06	6.55e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CAV1—prostate cancer	6.92e-06	6.54e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—LEP—prostate cancer	6.89e-06	6.52e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—RXRA—prostate cancer	6.87e-06	6.49e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—KDR—prostate cancer	6.86e-06	6.49e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—KDR—prostate cancer	6.84e-06	6.47e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CAV1—prostate cancer	6.83e-06	6.46e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—KDR—prostate cancer	6.75e-06	6.39e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—ESR1—prostate cancer	6.69e-06	6.33e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—ESR1—prostate cancer	6.67e-06	6.31e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—TYMS—prostate cancer	6.66e-06	6.29e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—COMT—prostate cancer	6.62e-06	6.26e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—GSTP1—prostate cancer	6.58e-06	6.23e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—ESR1—prostate cancer	6.58e-06	6.22e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—GSTM1—prostate cancer	6.58e-06	6.22e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—BAD—prostate cancer	6.53e-06	6.17e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—BAD—prostate cancer	6.51e-06	6.15e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—ITPR1—prostate cancer	6.48e-06	6.13e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—LPL—prostate cancer	6.46e-06	6.11e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—BAD—prostate cancer	6.42e-06	6.07e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—PIK3CG—prostate cancer	6.32e-06	5.98e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—APC—prostate cancer	6.32e-06	5.98e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—APC—prostate cancer	6.3e-06	5.96e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	6.3e-06	5.96e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—IRS1—prostate cancer	6.25e-06	5.91e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—EGF—prostate cancer	6.25e-06	5.91e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—CYP1A1—prostate cancer	6.24e-06	5.9e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—EGF—prostate cancer	6.23e-06	5.89e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—IRS1—prostate cancer	6.23e-06	5.89e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—APC—prostate cancer	6.22e-06	5.88e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	6.22e-06	5.88e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—ERCC2—prostate cancer	6.18e-06	5.85e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—EGF—prostate cancer	6.15e-06	5.82e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—IRS1—prostate cancer	6.15e-06	5.82e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—TYMS—prostate cancer	6.12e-06	5.79e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—GSK3B—prostate cancer	6.07e-06	5.74e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—GSTM1—prostate cancer	6.05e-06	5.72e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—GSK3B—prostate cancer	6.05e-06	5.72e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—INS—prostate cancer	5.99e-06	5.66e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—GSK3B—prostate cancer	5.97e-06	5.65e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—INS—prostate cancer	5.97e-06	5.64e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—LPL—prostate cancer	5.94e-06	5.62e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—INS—prostate cancer	5.89e-06	5.57e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CREBBP—prostate cancer	5.86e-06	5.54e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CREBBP—prostate cancer	5.84e-06	5.53e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—MTHFR—prostate cancer	5.81e-06	5.5e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—IGF1—prostate cancer	5.79e-06	5.47e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—IGF1—prostate cancer	5.77e-06	5.46e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CREBBP—prostate cancer	5.77e-06	5.45e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—EGFR—prostate cancer	5.76e-06	5.45e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—EGFR—prostate cancer	5.74e-06	5.43e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—CYP1A1—prostate cancer	5.74e-06	5.42e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—PPARA—prostate cancer	5.7e-06	5.39e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—IGF1—prostate cancer	5.7e-06	5.39e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—ERCC2—prostate cancer	5.69e-06	5.38e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—EGFR—prostate cancer	5.67e-06	5.36e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—MAP2K1—prostate cancer	5.6e-06	5.29e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	5.58e-06	5.27e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—PIK3CD—prostate cancer	5.56e-06	5.26e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	5.54e-06	5.24e-05	CbGpPWpGaD
Benzatropine—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	5.51e-06	5.21e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	5.51e-06	5.21e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—SERPINE1—prostate cancer	5.5e-06	5.2e-05	CbGpPWpGaD
Benzatropine—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	5.49e-06	5.19e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	5.48e-06	5.18e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	5.47e-06	5.17e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—KRAS—prostate cancer	5.44e-06	5.15e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—KRAS—prostate cancer	5.42e-06	5.13e-05	CbGpPWpGaD
Benzatropine—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	5.42e-06	5.12e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	5.41e-06	5.12e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—CAV1—prostate cancer	5.36e-06	5.07e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—KRAS—prostate cancer	5.35e-06	5.06e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—MTHFR—prostate cancer	5.35e-06	5.06e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—FGF2—prostate cancer	5.32e-06	5.03e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—FGF2—prostate cancer	5.31e-06	5.02e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—NOS3—prostate cancer	5.25e-06	4.96e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—PPARA—prostate cancer	5.25e-06	4.96e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—FGF2—prostate cancer	5.24e-06	4.95e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—NOS3—prostate cancer	5.23e-06	4.95e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—NOS3—prostate cancer	5.16e-06	4.88e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.12e-06	4.84e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—JAK2—prostate cancer	5.1e-06	4.82e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—JAK2—prostate cancer	5.09e-06	4.81e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—JAK2—prostate cancer	5.02e-06	4.75e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	5e-06	4.73e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	4.98e-06	4.71e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—MDM2—prostate cancer	4.98e-06	4.71e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—MDM2—prostate cancer	4.96e-06	4.69e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—CAV1—prostate cancer	4.93e-06	4.66e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	4.92e-06	4.65e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—ERBB2—prostate cancer	4.91e-06	4.64e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—MDM2—prostate cancer	4.9e-06	4.63e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—ERBB2—prostate cancer	4.89e-06	4.63e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—PIK3CG—prostate cancer	4.88e-06	4.62e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—PIK3CB—prostate cancer	4.85e-06	4.58e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—ERBB2—prostate cancer	4.83e-06	4.57e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	4.83e-06	4.57e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	4.77e-06	4.51e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CXCL8—prostate cancer	4.66e-06	4.4e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CXCL8—prostate cancer	4.64e-06	4.39e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—INS—prostate cancer	4.62e-06	4.37e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CXCL8—prostate cancer	4.58e-06	4.33e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CDKN1B—prostate cancer	4.55e-06	4.3e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	4.53e-06	4.29e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—CREBBP—prostate cancer	4.53e-06	4.28e-05	CbGpPWpGaD
Benzatropine—HRH1—GPCR downstream signaling—AKT1—prostate cancer	4.5e-06	4.25e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.49e-06	4.25e-05	CbGpPWpGaD
Benzatropine—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	4.48e-06	4.24e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	4.47e-06	4.23e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CASP3—prostate cancer	4.46e-06	4.21e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—IL2—prostate cancer	4.45e-06	4.21e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CASP3—prostate cancer	4.44e-06	4.2e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—IL2—prostate cancer	4.44e-06	4.19e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—IL6—prostate cancer	4.43e-06	4.19e-05	CbGpPWpGaD
Benzatropine—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	4.43e-06	4.19e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—IL6—prostate cancer	4.41e-06	4.17e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CASP3—prostate cancer	4.38e-06	4.15e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—IL2—prostate cancer	4.38e-06	4.14e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—IL6—prostate cancer	4.36e-06	4.12e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CCND1—prostate cancer	4.34e-06	4.1e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CCND1—prostate cancer	4.32e-06	4.09e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	4.3e-06	4.06e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—PIK3CD—prostate cancer	4.29e-06	4.06e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	4.28e-06	4.05e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CCND1—prostate cancer	4.27e-06	4.04e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—INS—prostate cancer	4.25e-06	4.02e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	4.23e-06	4e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—MMP9—prostate cancer	4.21e-06	3.98e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—MMP9—prostate cancer	4.2e-06	3.97e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	4.2e-06	3.97e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—PTEN—prostate cancer	4.19e-06	3.96e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	4.18e-06	3.96e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—PTEN—prostate cancer	4.17e-06	3.95e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—CREBBP—prostate cancer	4.17e-06	3.94e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—MMP9—prostate cancer	4.14e-06	3.92e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	4.13e-06	3.9e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—PTEN—prostate cancer	4.12e-06	3.9e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling by GPCR—AKT1—prostate cancer	4.08e-06	3.86e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	4.07e-06	3.85e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—NOS3—prostate cancer	4.05e-06	3.83e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	4.02e-06	3.8e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—EP300—prostate cancer	3.99e-06	3.78e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—EP300—prostate cancer	3.98e-06	3.76e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.95e-06	3.73e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—EP300—prostate cancer	3.93e-06	3.72e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—SRC—prostate cancer	3.88e-06	3.67e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—SRC—prostate cancer	3.87e-06	3.66e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—SRC—prostate cancer	3.82e-06	3.61e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—VEGFA—prostate cancer	3.78e-06	3.58e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	3.77e-06	3.56e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—STAT3—prostate cancer	3.74e-06	3.54e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—PIK3CB—prostate cancer	3.74e-06	3.54e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—STAT3—prostate cancer	3.73e-06	3.53e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—NOS3—prostate cancer	3.73e-06	3.53e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	3.72e-06	3.52e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—PTGS2—prostate cancer	3.71e-06	3.51e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—STAT3—prostate cancer	3.68e-06	3.48e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—MYC—prostate cancer	3.48e-06	3.29e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—TGFB1—prostate cancer	3.47e-06	3.28e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—MYC—prostate cancer	3.47e-06	3.28e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	3.46e-06	3.27e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.44e-06	3.26e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—MYC—prostate cancer	3.42e-06	3.24e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	3.42e-06	3.23e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—PTGS2—prostate cancer	3.41e-06	3.23e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—EGFR—prostate cancer	3.4e-06	3.22e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—EGFR—prostate cancer	3.39e-06	3.21e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—EGFR—prostate cancer	3.35e-06	3.17e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—PTEN—prostate cancer	3.23e-06	3.06e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—KRAS—prostate cancer	3.21e-06	3.04e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—KRAS—prostate cancer	3.2e-06	3.03e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—KRAS—prostate cancer	3.16e-06	2.99e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—EP300—prostate cancer	3.08e-06	2.92e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—PTEN—prostate cancer	2.97e-06	2.81e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	2.95e-06	2.79e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	2.94e-06	2.78e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	2.91e-06	2.75e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—TP53—prostate cancer	2.86e-06	2.7e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—TP53—prostate cancer	2.85e-06	2.69e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—EP300—prostate cancer	2.84e-06	2.68e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—TP53—prostate cancer	2.81e-06	2.66e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—IL6—prostate cancer	2.62e-06	2.47e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—IL6—prostate cancer	2.61e-06	2.47e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—IL6—prostate cancer	2.57e-06	2.43e-05	CbGpPWpGaD
Benzatropine—HRH1—Signaling Pathways—AKT1—prostate cancer	2.41e-06	2.28e-05	CbGpPWpGaD
Benzatropine—CHRM1—Signaling Pathways—AKT1—prostate cancer	2.41e-06	2.27e-05	CbGpPWpGaD
Benzatropine—CHRM2—Signaling Pathways—AKT1—prostate cancer	2.37e-06	2.25e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—PIK3CA—prostate cancer	2.28e-06	2.16e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.1e-06	1.98e-05	CbGpPWpGaD
Benzatropine—CYP2C19—Metabolism—AKT1—prostate cancer	1.86e-06	1.76e-05	CbGpPWpGaD
Benzatropine—CYP2D6—Metabolism—AKT1—prostate cancer	1.71e-06	1.62e-05	CbGpPWpGaD
